OA

Fortanix Brings Industry-Leading Data Security Solutions to Help Japanese Enterprises Prevent Data Breaches and Protect Sensitive Data

Retrieved on: 
Thursday, March 7, 2024

The company will exhibit its hybrid, multi-cloud data security capabilities at Security Days Spring 2024, which takes place March 12-15 in Tokyo.

Key Points: 
  • The company will exhibit its hybrid, multi-cloud data security capabilities at Security Days Spring 2024, which takes place March 12-15 in Tokyo.
  • “Japan is one of the top economies in the world, with many leading enterprises across industries that demand the highest level of data security,” said Anand Kashyap , CEO and co-founder of Fortanix.
  • “By implementing Fortanix DSM, we were able to secure data in SaaS applications such as Fortanix partner DreamArts' SmartDB.
  • Specifically, Fortanix will provide demos of its Data Security Manager (DSM) platform, along with key capabilities including External Key Manager.

Two AIP Publishing Journals Now Open Access Under Subscribe to Open Pilot

Retrieved on: 
Thursday, March 7, 2024

MELVILLE, N.Y., March 7, 2024 /PRNewswire/ -- Journal of Applied Physics and Physics of Plasmas, two of AIP Publishing's foremost scholarly publications, are now open access as part of a Subscribe to Open (S2O) pilot program.

Key Points: 
  • MELVILLE, N.Y., March 7, 2024 /PRNewswire/ -- Journal of Applied Physics and Physics of Plasmas, two of AIP Publishing's foremost scholarly publications, are now open access as part of a Subscribe to Open (S2O) pilot program.
  • The switch to open access (OA) is a result of our institutional subscribers renewing their subscriptions and supporting the S2O pilot program.
  • Announced in July 2023 , AIP Publishing's S2O pilot program is a demonstration of the publisher's commitment to equity, accessibility, and open science in scholarly publishing.
  • "When we announced our Subscribe to Open pilot last year, it was with the hope that these two journals would make the transition to open access, and we're excited that day has arrived," said Penelope Lewis, Chief Publishing Officer at AIP Publishing.

Rejuvenate Bio Announces Partnership with Leading Animal Health Company to Develop Gene Therapy for Canine Osteoarthritis

Retrieved on: 
Wednesday, February 14, 2024

Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.

Key Points: 
  • Rejuvenate Bio today announced a partnership with a leading animal health company for the development and commercialization of its novel gene therapy technology for the treatment of canine osteoarthritis (OA), a complex chronic disease that affects dogs’ mobility and overall quality of life.
  • This agreement with the global company follows the agreement reached in 2022 with Phibro Animal Health and further validates the gene therapy technology developed by Rejuvenate Bio and their strategy to develop their breakthrough technology in both animal health and human health.
  • Canine osteoarthritis (OA) presents a significant challenge, being both painful and progressive, with a concerning prevalence rate.
  • “This partnership with a leading animal health company validates our technology and approach of utilizing gene therapy to treat chronic age-related diseases and ensures that this therapy will reach the dogs that need it.

Zoetis Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Tuesday, February 13, 2024

(NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.

Key Points: 
  • (NYSE: ZTS) today reported its financial results for the fourth quarter and full year 2023 as well as provided full year guidance for 2024.
  • The company reported revenue of $2.2 billion for the fourth quarter of 2023, which was an increase of 8% compared with the fourth quarter of 2022, on both a reported and operational1 basis.
  • In the fourth quarter of 2023:
    Revenue in the U.S. segment was $1.2 billion, an increase of 9% compared with the fourth quarter of 2022.
  • Zoetis will host a webcast and conference call at 8:30 a.m. (ET) today, during which company executives will review fourth quarter and full year 2023 results, discuss financial guidance and respond to questions from financial analysts.

AeroBand's New Releases Shine at NAMM Show 2024, Garnering Rapid Popularity

Retrieved on: 
Thursday, February 8, 2024

For individuals with finger ailments and sensitivity, including children and the elderly, this breakthrough technology opens up musical possibilities for a wider audience.

Key Points: 
  • For individuals with finger ailments and sensitivity, including children and the elderly, this breakthrough technology opens up musical possibilities for a wider audience.
  • For beginners and those who had previously given up learning the guitar, AeroBand Guitar undoubtedly addresses the pain issue during practice.
  • During the Premier Guitar interview , the AeroBand team showcased a unique application designed specifically for the AeroBand Guitar.
  • At this year's NAMM Show, AeroBand takes the lead and showcases the highly anticipated product - PocketDrum 2 Plus.

Global Modified Polyphenylene Ether (mPPE) Market Review 2019-2023 and Forecast to 2029: Analysis of Major Growth Trends, R&D, Technology Updates, Statutory Regulations and Emerging Applications - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 31, 2024

The "Modified Polyphenylene Ether (mPPE) - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Modified Polyphenylene Ether (mPPE) - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.
  • The report reviews, analyzes and projects the global Modified Polyphenylene Ether (mPPE) market for the period 2019-2029 in terms of market value in US$ and the compound annual growth rates (CAGRs) projected from 2023 through 2029.
  • Automotive & Transportation and Electrical & Electronics industries are the leading consumers of mPPE worldwide with an estimated market share of around 29% each in 2023, followed by OA Equipment & Appliances estimated at 21%.
  • Global market share analysis for mPPE is provided based on the segmentation mentioned above; and current market size estimations and revenue projections given for the analysis period through 2029
    The study discusses major growth trends, R&D, technology updates, statutory regulations and emerging applications of mPPE that influence the market growth, wherever applicable
    Key business trends focusing on product innovations/developments, capacity expansions, M&As, JVs and other recent industry developments by the major players
    The market for end-use applications of mPPE analyzed in this report includes:

2024 OREF Clinical Research Award Celebrates Study of Local Gene Therapy to Treat Osteoarthritis

Retrieved on: 
Friday, February 2, 2024

ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).

Key Points: 
  • ROSEMONT, Ill. , Feb. 2, 2024 /PRNewswire/ -- The 2024 Orthopaedic Research and Education Foundation (OREF) Clinical Research Award was presented to Christopher H. Evans, PhD (Mayo Clinic), Steven C. Ghivizzani, PhD (University of Florida), and Paul D. Robbins, PhD (University of Minnesota), for their research on local gene therapy for osteoarthritis (OA).
  • Together, the team spearheaded the research from a laboratory concept to human clinical trials over the course of 30 years.
  • The OREF Award recognizes outstanding clinical research related to musculoskeletal disease or injury.
  • Evans, Ghivizzani and Robbins co-founded an arthritis gene therapy startup company, Genascence Corporation, which will help fund future clinical trials.

Kappa Delta Elizabeth Winston Lanier Award Presented to The ANCHOR Group for Improving Quality of Care for Young Patients With Pre-Arthritic Hip Conditions

Retrieved on: 
Friday, February 2, 2024

This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.

Key Points: 
  • This award recognizes research in musculoskeletal disease or injury with great potential to advance patient care.
  • "In the early 2000s, the orthopaedic community lacked an understanding of pre-arthritic hip disease diagnoses and treatments.
  • "Over the past 20 years, access to quality care for young patients with pre-arthritic hip disease has markedly improved" said Dr. Clohisy.
  • "We now have surgeons and health care teams who can deliver a comprehensive approach to manage the full spectrum of pre-arthritic hip disease.

Enovis Introduces the DonJoy ROAM™ OA Knee Brace

Retrieved on: 
Thursday, January 25, 2024

WILMINGTON, DE, Jan. 25, 2024 (GLOBE NEWSWIRE) --  Enovis™ Corporation (“Enovis” or the “Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today that its DJO, LLC subsidiary has launched its new DonJoy® ROAM™ OA knee brace for patients with osteoarthritis or other knee pain and instability.

Key Points: 
  • WILMINGTON, DE, Jan. 25, 2024 (GLOBE NEWSWIRE) --  Enovis™ Corporation (“Enovis” or the “Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, announced today that its DJO, LLC subsidiary has launched its new DonJoy® ROAM™ OA knee brace for patients with osteoarthritis or other knee pain and instability.
  • Designed for conservative care, preparation for surgery, or for postoperative knee protection, ROAM OA is ideal for a wide range of patients who want to maintain or increase activity.
  • “ROAM OA represents the next generation of unloader knee braces for active patients with pain due to osteoarthritis or other causes," said Terry Ross, Group President of Enovis Prevention & Recovery.
  • “It’s effective and easy for patients to use and easy for providers to prescribe, even for patients who would otherwise need a customized device.”
    For more information about the ROAM OA knee brace, visit www.enovis.com/roamoa .

James Leech Joins Moximed as Chief Financial and Strategy Officer

Retrieved on: 
Thursday, January 18, 2024

Moximed , a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that James Leech has joined the company as Chief Financial and Strategy Officer.

Key Points: 
  • Moximed , a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that James Leech has joined the company as Chief Financial and Strategy Officer.
  • “James adds significant financial and business strategy expertise to our executive team,” said Anton Clifford, Ph.D., founder and CEO of Moximed.
  • “He’s achieved success as a founder, financier, and operator, particularly with companies at a growth stage similar to Moximed.
  • “I am excited to join Moximed and help lead the growth of the business,” said Mr. Leech.